vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and Sachem Capital Corp. (SACH). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $12.0M, roughly 1.1× Sachem Capital Corp.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -34.7%, a 43.0% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -18.8%). Over the past eight quarters, Sachem Capital Corp.'s revenue compounded faster (-13.4% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
FENC vs SACH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $12.0M |
| Net Profit | $-4.8M | $997.0K |
| Gross Margin | — | — |
| Operating Margin | -18.5% | -3.1% |
| Net Margin | -34.7% | 8.3% |
| Revenue YoY | 73.8% | -18.8% |
| Net Profit YoY | -141.1% | 119.7% |
| EPS (diluted) | $-0.17 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $12.5M | $12.0M | ||
| Q2 25 | $9.7M | $10.8M | ||
| Q1 25 | $8.8M | $11.4M | ||
| Q4 24 | $7.9M | $10.8M | ||
| Q3 24 | $7.0M | $14.8M | ||
| Q2 24 | $7.3M | $15.1M | ||
| Q1 24 | $25.4M | $16.8M |
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-638.0K | $997.0K | ||
| Q2 25 | $-3.2M | $1.9M | ||
| Q1 25 | $-1.2M | $904.0K | ||
| Q4 24 | $-2.0M | $-36.1M | ||
| Q3 24 | $-5.7M | $-5.1M | ||
| Q2 24 | $-5.6M | $-3.1M | ||
| Q1 24 | $12.8M | $4.7M |
| Q4 25 | -18.5% | — | ||
| Q3 25 | -1.5% | -3.1% | ||
| Q2 25 | -28.3% | 9.9% | ||
| Q1 25 | -9.2% | 9.0% | ||
| Q4 24 | -11.8% | -131.1% | ||
| Q3 24 | -74.6% | -32.6% | ||
| Q2 24 | -69.4% | -20.6% | ||
| Q1 24 | 54.2% | 25.4% |
| Q4 25 | -34.7% | — | ||
| Q3 25 | -5.1% | 8.3% | ||
| Q2 25 | -32.7% | 17.5% | ||
| Q1 25 | -13.3% | 7.9% | ||
| Q4 24 | -25.0% | -335.6% | ||
| Q3 24 | -82.2% | -34.2% | ||
| Q2 24 | -76.5% | -20.2% | ||
| Q1 24 | 50.6% | 27.8% |
| Q4 25 | $-0.17 | — | ||
| Q3 25 | $-0.02 | $0.00 | ||
| Q2 25 | $-0.11 | $0.02 | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.02 | $-0.79 | ||
| Q3 24 | $-0.21 | $-0.13 | ||
| Q2 24 | $-0.20 | $-0.09 | ||
| Q1 24 | $0.41 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $12.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | $175.6M |
| Total Assets | $70.6M | $484.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | — | ||
| Q3 25 | $21.9M | $12.6M | ||
| Q2 25 | $18.7M | $23.5M | ||
| Q1 25 | $22.7M | $25.8M | ||
| Q4 24 | $26.6M | $19.6M | ||
| Q3 24 | $40.3M | $7.4M | ||
| Q2 24 | $43.1M | $12.4M | ||
| Q1 24 | $51.2M | $56.8M |
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | $230.2M | ||
| Q4 24 | $19.3M | $230.2M | ||
| Q3 24 | $32.1M | $264.7M | ||
| Q2 24 | $31.8M | $264.7M | ||
| Q1 24 | $31.3M | $288.4M |
| Q4 25 | $35.5M | — | ||
| Q3 25 | $-4.5M | $175.6M | ||
| Q2 25 | $-7.5M | $177.9M | ||
| Q1 25 | $-5.9M | $179.3M | ||
| Q4 24 | $-5.9M | $181.7M | ||
| Q3 24 | $-5.2M | $220.6M | ||
| Q2 24 | $-1.4M | $230.2M | ||
| Q1 24 | $3.0M | $237.4M |
| Q4 25 | $70.6M | — | ||
| Q3 25 | $49.3M | $484.4M | ||
| Q2 25 | $44.9M | $501.8M | ||
| Q1 25 | $46.4M | $491.4M | ||
| Q4 24 | $44.9M | $492.0M | ||
| Q3 24 | $58.9M | $555.5M | ||
| Q2 24 | $63.2M | $586.3M | ||
| Q1 24 | $69.2M | $626.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | 10.40× | 1.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $4.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 4.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $1.5M | $4.9M | ||
| Q2 25 | $-3.7M | $501.0K | ||
| Q1 25 | $-4.3M | $191.0K | ||
| Q4 24 | $-1.5M | $12.9M | ||
| Q3 24 | $-2.2M | $2.3M | ||
| Q2 24 | $-8.4M | $7.0M | ||
| Q1 24 | $39.0M | $4.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.95× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.04× | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
